IKZF1 gene deletions have been associated with a poor outcome in pediatric precursor B-
cell acute lymphoblastic leukemia. To assess the prognostic relevance of IKZF1 deletions for …

Deletions in IKZF1 are found in~ 15% of children with B-cell precursor acute lymphoblastic
leukemia (BCP-ALL). There is strong evidence for the poor prognosis of IKZF1 deletions …

Improved personalized adjustment of primary therapy to the perceived risk of relapse by
using new prognostic markers for treatment stratification may be beneficial to patients with …

Purpose Somatic deletions that affect the lymphoid transcription factor–coding gene IKZF1
have previously been reported as independently associated with a poor prognosis in …

Alterations in the IKZF1 gene are associated with poor prognosis in pediatric B‐cell acute
lymphoblastic leukemia (B‐ALL). We examined the relationship between IKZF1 alterations …

Purpose Although IKZF1 deletion (IKZF1 del) confers a higher risk of relapse in childhood B-
cell acute lymphoblastic leukemia (B-ALL), it is uncertain whether treatment intensification …

Paediatric B‐cell precursor acute lymphoblastic leukaemias (BCP ALL) with IKZF 1 deletions
(∆ IKZF 1) are associated with a poor outcome. However, there are conflicting data as to …

Despite current risk‐directed therapy, approximately 15–20% of pediatric patients with acute
lymphoblastic leukemia (ALL) have relapses. Recent genome‐wide analyses have …

Genetic alterations of Ikaros family zinc finger protein 1 (IKZF 1), point mutations in Janus
kinase 2 (JAK 2), and overexpression of cytokine receptor‐like factor 2 (CRLF 2) were …

New prognostic markers are needed for upfront identification of patients with acute
lymphocytic leukemia with a high risk of relapse or who are not likely to respond to the most …